Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study.
BACKGROUND
The genetic cause of amyotrophic lateral sclerosis (ALS) is not well understood. Finland is a well suited location for a genome-wide association study of ALS because the incidence of the disease is one of the highest in the world, and because the genetic homogeneity of the Finnish population enhances the ability to detect risk loci. We aimed to identify genetic risk factors for ALS in the Finnish population.


METHODS
We did a genome-wide association study of Finnish patients with ALS and control individuals by use of Illumina genome-wide genotyping arrays. DNA was collected from patients who attended an ALS specialty clinic that receives referrals from neurologists throughout Finland. Control samples were from a population-based study of elderly Finnish individuals. Patients known to carry D90A alleles of the SOD1 gene (n=40) were included in the final analysis as positive controls to assess whether our genome-wide association study was able to detect an association signal at this locus.


RESULTS
We obtained samples from 442 patients with ALS and 521 control individuals. After quality control filters were applied, 318 167 single nucleotide polymorphisms (SNPs) from 405 people with ALS and 497 control individuals were available for analysis. We identified two association peaks that exceeded genome-wide significance. One was located on chromosome 21q22 (rs13048019, p=2·58×10(-8)), which corresponds to the autosomal recessive D90A allele of the SOD1 gene. The other was detected in a 232 kb block of linkage disequilibrium (rs3849942, p=9·11×10(-11)) in a region of chromosome 9p that was previously identified in linkage studies of families with ALS. Within this region, we defined a 42-SNP haplotype that was associated with significantly increased risk of ALS (p=7·47×10(-33) when people with familial ALS were compared with controls, odds ratio 21·0, 95% CI 11·2-39·1) and which overlapped with an association locus recently reported for frontotemporal dementia. For the 93 patients with familial ALS, the population attributable risk for the chromosome 9p21 locus was 37·9% (95% CI 27·7-48·1) and that for D90A homozygosity was 25·5% (16·9-34·1).


CONCLUSIONS
The chromosome 9p21 locus is a major cause of familial ALS in the Finnish population. Our data suggest the presence of a founder mutation for chromosome 9p21-linked ALS. Furthermore, the overlap with the risk haplotype recently reported for frontotemporal dementia provides further evidence of a shared genetic cause for these two neurodegenerative diseases.


BACKGROUND
National Institutes of Health and National Institute on Aging, Microsoft Research, ALS Association, Helsinki University Central Hospital, Finnish Academy, Finnish Medical Society Duodecim, and Kuopio University.
Laaksovirta
Hannu
H
Department of Neurology, Helsinki University Central Hospital and Molecular Neurology Programme, Biomedicum, University of Helsinki, Helsinki, Finland.
Peuralinna
Terhi
T
Schymick
Jennifer C
JC
Scholz
Sonja W
SW
Lai
Shaoi-Lin
SL
Myllykangas
Liisa
L
Sulkava
Raimo
R
Jansson
Lilja
L
Hernandez
Dena G
DG
Gibbs
J Raphael
JR
Nalls
Michael A
MA
Heckerman
David
D
Tienari
Pentti J
PJ
Traynor
Bryan J
BJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000690:Amyotrophic Lateral Sclerosis / Q000201:enzymology / Q000453:epidemiology* / Q000235:genetics*; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics*; D015331:Cohort Studies; D005260:Female; D005387:Finland / Q000453:epidemiology; D056426:Genetic Loci / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000453:epidemiology / Q000235:genetics; D055106:Genome-Wide Association Study / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D013482:Superoxide Dismutase / Q000235:genetics; D000072105:Superoxide Dismutase-1; D055815:Young Adult
C000606290:SOD1 protein, human; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1
Acta Neurol Scand. 1983 Jan;67(1):41-7
6601351
Neurology. 2001 Jun 26;56(12):1690-6
11425935
Hum Mol Genet. 1999;8(10):1913-23
10469845
J Neurol Sci. 1994 Jul;124 Suppl:96-107
7807156
Neurology. 2006 Mar 28;66(6):839-44
16421333
Am J Hum Genet. 2008 Feb;82(2):453-63
18252225
Nat Genet. 1995 May;10(1):61-6
7647793
Nat Genet. 2001 Aug;28(4):309-10
11479587
Neurology. 2007 Mar 27;68(13):1002-7
17389304
BMC Neurol. 2008 Aug 29;8:32
18755042
J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):196-203
20562461
Lancet Neurol. 2007 Oct;6(10):869-77
17827064
Nat Genet. 2008 Jan;40(1):29-31
18084291
Hum Mol Genet. 2009 Apr 15;18(8):1524-32
19193627
N Engl J Med. 2001 May 31;344(22):1688-700
11386269
Int J Epidemiol. 1978 Jun;7(2):175-82
681063
Lancet Neurol. 2007 Apr;6(4):322-8
17362836
Neuropathol Appl Neurobiol. 1998 Apr;24(2):104-17
9634206
Nat Genet. 2010 Mar;42(3):234-9
20154673
Neurology. 2007 Feb 20;68(8):600-2
17310031
N Engl J Med. 2007 Aug 23;357(8):775-88
17671248
Brain. 2006 Apr;129(Pt 4):868-76
16495328
Bioinformatics. 2005 Jan 15;21(2):263-5
15297300
Annu Rev Genomics Hum Genet. 2001;2:103-28
11701645
Am J Hum Genet. 2007 Sep;81(3):559-75
17701901
Hum Mol Genet. 2008 Mar 1;17(5):768-74
18057069
Arch Neurol. 2007 Feb;64(2):240-5
17296840
J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):867-71
12810769
Neurology. 2009 May 12;72(19):1669-76
19433740
Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9004-9
19451621
Nat Genet. 2009 Oct;41(10):1083-7
19734901